IndustryCompany release

Quanterix Q3 revenue reaches $35.0M, up 6.3% on Q2, as diagnostics plans take shape

🇺🇸 Quanterix Corp (QTRX) · Mon 09 Nov 2026

The Simoa maker reported third-quarter revenue ahead of expectations and set out neurology assay launches, a 2027 IVD submission plan for HD-X and updated 2026 guidance.

Quanterix presented its third-quarter 2026 results on 9 November, reporting revenue of $35.0M. The company said this was ahead of expectations and 6.3% higher than in the second quarter.

Within the quarter, volumes of the Lucent AD test doubled, and bookings at its Accelerator Lab grew. The summary of the announcement gives no further figures on test volumes or bookings.

Quanterix also outlined its product plans. These include launches of new Simoa neurology assays and a plan to make an in vitro diagnostic (IVD) submission for the HD-X platform in 2027. The details of the assays, the target market and the regulatory route were not available in the material reviewed.

The company updated its 2026 guidance. The results follow its acquisitions of Emission and Akoya Biosciences, although the available information does not say how these deals contributed to the quarter or what the revised guidance figures are.

What it means for your team

  • A planned 2027 IVD submission for HD-X signals a move towards regulated diagnostic use of the platform; regulatory teams should watch for the chosen pathway and jurisdictions.
  • Doubled Lucent AD test volume suggests growing use of blood-based neurology testing, which may matter for laboratories and payers assessing access and reimbursement.
  • Quality and compliance teams working with Quanterix products should look out for integration effects from the Emission and Akoya acquisitions, which the available information does not detail.

Company's press release (SEC filing): Quanterix Corp ↗

Article written by VigiEye from the official source (Quanterix Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →